BNP Paribas Asset Management
KALV

BNP Paribas Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

BNP Paribas Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-952
Closed -$19.2K – 2300
2026
Q1 		$19.2K Buy
952
+339
+55% +$5.46K ﹤0.01% 2047
2025
Q4 		$10K Buy
+613
New +$8.12K ﹤0.01% 2141

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BNP Paribas Asset Management's KALV Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 952 shares — an estimated $19.2K sold.

BNP Paribas Asset Management first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $19.2K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 952 KalVista Pharmaceuticals shares in Q2 2026, an estimated $19.2K.
  • BNP Paribas Asset Management first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • BNP Paribas Asset Management's KalVista Pharmaceuticals position peaked at $19.2K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.